Assoc Prof Dr. Chong Qiu | Nanomedicine Awards | Young Scientist Award

Posted on by ScienceFather

Assoc Prof Dr. Chong Qiu | Nanomedicine Awards | Young Scientist Award

Assoc Prof Dr. Chong Qiu, China Academy of Chinese Medical Sciences, China

Associate Professor Chong Qiu, Ph.D., is a prominent researcher at the Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing. He earned his bachelor’s and doctoral degrees from the School of Pharmaceutical Science, Peking University, in 2014 and 2019, respectively. Dr. Qiu’s research focuses on advanced nanocarriers for targeted drug delivery, including siRNA and protein delivery systems. He is an active Young Scientist Board Member for several journals and has published extensively, with notable papers in Nature Communications and Journal of Nanobiotechnology. His work has garnered significant attention and impact in the fields of nanomedicine and drug delivery.

Professional Profile:

Orcid

Suitability Summary for Young Scientist Award: Associate Professor Chong Qiu

Associate Professor Chong Qiu is an exemplary candidate for the Young Scientist Award. His pioneering research in nanocarriers for drug delivery, combined with his impressive publication record and leadership roles, highlights his exceptional potential and influence in the scientific community. His achievements and innovative contributions make him a standout nominee for this prestigious award

šŸŽ“Education:

Dr. Chong Qiu earned his Ph.D. in Pharmaceutical Sciences from the School of Pharmaceutical Science at Peking University, Beijing, China, in 2019. He completed his Bachelorā€™s Degree in Pharmaceutical Sciences at the same institution in 2014.

šŸ¢Work Experience:

Dr. Chong Qiu has been serving as an Associate Professor at the Artemisinin Research Center and the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing, since 2019. In addition to his role at the Research Center, he is an ongoing Young Scientist Board Member for the Asian Journal of Pharmaceutical Sciences, iMeta, and Traditional Medicine Research and Exploration

šŸ…Awards and Recognition:

Dr. Chong Qiu has an extensive publication record in high-impact journals, including notable works in Nature Communications and the Journal of Nanobiotechnology. His research has garnered significant recognition and has made substantial contributions to the fields of nanomedicine and drug delivery.

Publication Top Notes:

  • Photoaffinity Probe-Based Antimalarial Target Identification of Artemisinin in the Intraerythrocytic Developmental Cycle of Plasmodium falciparum
  • Enhanced Tumor Penetration Across the Blood-Brain Barrier: Endoplasmic Reticulum Membrane Hybrid siRNA Nanoplexes
  • Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery
  • Advanced Strategies for Nucleic Acids and Small-Molecular Drugs in Combined Anticancer Therapy
  • Anemoside B4 Alleviates Neuropathic Pain Through Inhibiting Inflammation

 

 

 

Assoc. Prof. Dr. Hui Xiong | Nanomedicine Award | Best Researcher Award

Posted on by ScienceFather

Assoc. Prof. Dr. Hui Xiong | Nanomedicine Award | Best Researcher Award

Assoc. Prof. Dr. Hui Xiong, China Pharmaceutical University, china

Hui Xiong is an accomplished researcher and associate professor at China Pharmaceutical University, specializing in the development of multifunctional nanosystems for cancer therapy. With a Ph.D. in Biotechnology, her work focuses on innovative drug delivery platforms and combination therapies targeting various aspects of tumor biology. Through her extensive research experience and numerous publications, she has made significant contributions to advancing cancer treatment strategies. Additionally, Hui Xiong has secured funding from prestigious foundations to support her groundbreaking research endeavors.

Professional Profile:

Scopus

šŸŽ“ Education and Work Background

Dr. Hui Xiong holds a Ph.D. in Biotechnology from Banasthali Vidhyapith Rajasthan, completed in 2018 with a remarkable score of 81.36%. Prior to that, she earned her M.Sc. in Biotechnology from the same institution in 2013, achieving a commendable score of 76.35%. Her academic journey began with a Bachelor’s degree in Biotechnology from Sam Higginbottom University of Agriculture, Technology and Science Prayagraj, where she graduated with an outstanding CGPA of 9.96 in 2011.

šŸ’¼ Work Experience

Dr. Hui Xiong has served as an Associate Professor in the Department of Pharmaceutics at China Pharmaceutical University (CPU) since 2017, contributing significantly to the field of pharmaceutical sciences. Prior to her current role, she worked as a Postdoctoral Researcher at CPU from 2017 to 2020, where she made notable contributions to research in pharmaceutics. Dr. Xiong embarked on her academic journey as a Ph.D. student in the same department at CPU from 2012 to 2017, showcasing her dedication to advancing pharmaceutical research. Her educational foundation was laid during her undergraduate years at the College of Pharmacy, Hubei University of Chinese Medicine, where she honed her skills and passion for the field from 2008 to 2012.

šŸ† Foundations

Dr. Hui Xiong’s research endeavors have garnered recognition and support from prestigious organizations such as the National Natural Science Foundation of China. Her innovative projects have received funding from this esteemed foundation, underscoring the significance and impact of her contributions to the field of pharmaceutical sciences. This funding serves as a testament to Dr. Xiong’s expertise and the importance of her research in advancing scientific knowledge and addressing critical challenges in the pharmaceutical industry.

Publication Top Notes:

  1. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment – 2024
    • Published in: Journal of Colloid and Interface Science
  2. Recent Progress in Anti-Tumor Nanodrugs Based on Tumor Microenvironment Redox Regulation – 2024
    • Published in: Small
  3. Bioengineered Nanospores Selectively Blocking LC3-Associated Phagocytosis in Tumor-Associated Macrophages Potentiate Antitumor Immunity – 2023
    • Published in: ACS Nano
  4. Modified chitosan nanogel-polymersomes for oral co-delivery of oxaliplatin and rapamycin for synergistic chemotherapy – 2022
    • Published in: Journal of Drug Delivery Science and Technology
  5. Metabolic Symbiosis-Blocking Nano-Combination for Tumor Vascular Normalization Treatment – 2022
    • Published in: Advanced Healthcare Materials

 

Mr.Manish Kumar | Nanomedicine Award | Best Scholar Award

Posted on by ScienceFather

Mr.Manish Kumar | Nanomedicine Award | Best Scholar Award

Mr.Manish Kumar, Indian Institute of Technology BHU, India

Manish Kumar, currently enrolled in a Ph.D. program at the Department of Pharmaceutical Engineering and Technology, Indian Institute of Technology (BHU), Varanasi, India, demonstrates a strong academic background and a passion for pharmaceutical research. With a Master’s degree in Pharmaceutics from Sardar Bhagwan Singh Post Graduate Institute of Bio Medical Sciences & Research, Dehradun, and a Bachelor’s degree in Pharmacy from HNBGU, he has consistently excelled in his academic pursuits. Manish has garnered recognition for his contributions, including the International Best Researcher in Pharmacy Award and the honor of being named an Honorary Rosalind Member of London Journals Press. His professional experience spans roles as a Teaching Assistant at IIT BHU and an Assistant Professor at Tarawati Institute of Biomedical and Allied Science, Roorkee. Additionally, he has received practical training in both pharmaceutical production and hospital settings, showcasing a well-rounded skill set and a dedication to the field of pharmaceutical sciences.

Professional Profile:

Orcid

Google Scholar

šŸ“š Education:

Manish Kumar is currently pursuing a Ph.D. in Pharmaceutical Engineering and Technology at IIT (BHU), Varanasi, India, with a commendable CGPA of 7.6. He holds a Master’s degree (M. Pharm) in Pharmaceutics from Sardar Bhagwan Singh Post Graduate Institute of Bio Medical Sciences & Research, Dehradun, where he achieved a notable 79% score. Prior to that, he completed his Bachelor’s degree (B. Pharm) in Pharmaceutical Sciences from HNBGU with a commendable 75% score. Manish completed his secondary education from S. G. R. R. Race Course, Dehradun, securing 70% in the CBSE board exams.

šŸ† Awards:

Manish Kumar has been recognized as the International Best Researcher in Pharmacy, receiving the prestigious Research Leadership Award of the Year 2020 from IJRULA Awards. Additionally, he was appointed as an Honorary Rosalind Member of London Journals Press (#DA29060) in August 2020, acknowledging his outstanding contributions to the field.

šŸ‘Øā€šŸ« Experiences:

Manish Kumar has served as a Teaching Assistant at the Department of Pharmaceutical Engineering and Technology, IIT BHU, Varanasi-221005, where he contributed to various courses including Dosage Formulation Design, Pharmacokinetics, Advanced Biopharmaceutics, and Novel Drug Delivery Systems. He also worked as an Assistant Professor at the Tarawati Institute of Biomedical and Allied Science in Roorkee Saliyar, Uttarakhand. Additionally, Manish completed one-month industrial training in Production and QA at IPCA Laboratories Ltd., Dehradun, Uttarakhand, and underwent hospital training at HNB Base Hospital, Srinagar Garhwal, Uttarakhand.

Publication Top Notes:

  1. Preparation of luliconazole nanocrystals loaded hydrogel for improvement of dissolution and antifungal activity – 2019
    • Published in: Heliyon
    • Cited by: 88
  2. Electrospun nanofiber-based drug delivery platform: advances in diabetic foot ulcer management – 2021
    • Published in: Expert Opinion on Drug Delivery
    • Cited by: 43
  3. Analysis of isolated power systems for village electrification – 2010
    • Published in: Energy for Sustainable Development
    • Cited by: 41
  4. Targeted drug nanocrystals for pulmonary delivery: a potential strategy for lung cancer therapy – 2020
    • Published in: Expert Opinion on Drug Delivery
    • Cited by: 39
  5. Nanocarriers for tuberculosis therapy: design of safe and effective drug delivery strategies to overcome the therapeutic challenges – 2022
    • Published in: Journal of Drug Delivery Science and Technology
    • Cited by: 10